A detailed history of Vanguard Group Inc transactions in Simulations Plus, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,135,105 shares of SLP stock, worth $54.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,135,105
Previous 1,122,469 1.13%
Holding current value
$54.2 Million
Previous $50.2 Million 7.01%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$37.48 - $44.74 $473,597 - $565,334
12,636 Added 1.13%
1,135,105 $46.7 Million
Q4 2023

Feb 14, 2024

BUY
$33.36 - $45.71 $119,795 - $164,144
3,591 Added 0.32%
1,122,469 $50.2 Million
Q3 2023

Nov 14, 2023

BUY
$40.03 - $51.51 $200,510 - $258,013
5,009 Added 0.45%
1,118,878 $46.7 Million
Q2 2023

Aug 14, 2023

SELL
$40.45 - $48.0 $208,964 - $247,968
-5,166 Reduced 0.46%
1,113,869 $48.3 Million
Q1 2023

May 15, 2023

SELL
$34.96 - $43.94 $2,691 - $3,383
-77 Reduced 0.01%
1,119,035 $49.2 Million
Q4 2022

Feb 10, 2023

SELL
$36.55 - $51.15 $247,406 - $346,234
-6,769 Reduced 0.6%
1,119,112 $40.9 Million
Q3 2022

Nov 14, 2022

BUY
$47.75 - $66.88 $958,438 - $1.34 Million
20,072 Added 1.82%
1,125,881 $54.7 Million
Q2 2022

Aug 12, 2022

BUY
$40.55 - $51.76 $701,677 - $895,655
17,304 Added 1.59%
1,105,809 $54.6 Million
Q1 2022

May 13, 2022

BUY
$36.56 - $50.98 $684,110 - $953,937
18,712 Added 1.75%
1,088,505 $55.5 Million
Q4 2021

Feb 14, 2022

BUY
$37.1 - $57.45 $1.92 Million - $2.98 Million
51,885 Added 5.1%
1,069,793 $50.6 Million
Q3 2021

Nov 12, 2021

BUY
$38.45 - $55.66 $272,456 - $394,406
7,086 Added 0.7%
1,017,908 $40.2 Million
Q2 2021

Aug 13, 2021

BUY
$49.67 - $68.96 $50.2 Million - $69.7 Million
1,010,822 New
1,010,822 $55.5 Million

Others Institutions Holding SLP

About Simulations Plus, Inc.


  • Ticker SLP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Health Information Services
  • Shares Outstandng 20,297,700
  • Market Cap $968M
  • Description
  • Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which sim...
More about SLP
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.